Regeneron ' s Blood Cancer Therapy Faces Setback as FDA Raises Trial Concerns Regeneron ' s Blood Cancer Therapy Faces Setback as FDA Raises Trial Concerns

Regeneron Pharmaceuticals said on Monday the U.S. FDA has declined approval for its blood cancer therapy for two forms of lymphoma, raising concerns over the progress of...Reuters Health Information
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Hematology-Oncology Source Type: news